Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction. Experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. | Zendy

Gabriel I. Barbash | Zendy; Harvey D. White | Zendy; Michaela Modan | Zendy; Rafael Díaz | Zendy; J R Hampton | Zendy; J Heikkilä | Zendy; Arni Kristinsson | Zendy; S Moulopoulos | Zendy; Ernesto Paolasso | Zendy; T Van der Werf | Zendy

Open Access

Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction. Experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.

Author(s) -

Gabriel I. Barbash,

Harvey D. White,

Michaela Modan,

Rafael Díaz,

J R Hampton,

J Heikkilä,

Arni Kristinsson,

S Moulopoulos,

Ernesto Paolasso,

T Van der Werf

Publication year - 1993

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/01.cir.87.1.53

Subject(s) - medicine , streptokinase , killip class , myocardial infarction , tissue plasminogen activator , diabetes mellitus , univariate analysis , stroke (engine) , surgery , cardiology , multivariate analysis , percutaneous coronary intervention , endocrinology , mechanical engineering , engineering

Despite the fact that smoking is a well-established risk factor for the development of coronary artery disease, some investigators have noted that hospital mortality after acute myocardial infarction is lower in patients who smoke than in nonsmoking patients. To evaluate the association of smoking with mortality during hospitalization after thrombolytic therapy and 6 months afterward, we analyzed the results of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research